MATERIAL AND METHODS
In this prospective single-center study, 166 consecutive patients who underwent MpMRI for prostate cancer diagnosis between April’19 and December’19 were evaluated. Ethical approval was obtained from a local committee. Oral and written consents were obtained from all patients. Twelve patients with unsuitable image quality for evaluation, 26 patients with bx performed previously, without cognitive fusion biopsy in our hospital and with prostate cancer treatment before testing, and 44 patients with no tissue diagnosis due to PI-RADS-1 or refusing biopsy were excluded from the study. A total of 106 lesions of 84 patients diagnosed with TRUS-guided CF-Bx in our hospital were included in the final study group. Patient age, serum PSA value, PSAd, and prostate volume were recorded. The prostate MpMRI examined in the study was performed with a 1.5T Siemens Magnetom Aera MRI device with 18 channels pelvic coil according to the protocols shown in belowTable-1 . All sequences were assessed on a SYNGO.VIA-workstation.